Results 31 to 40 of about 48,562 (198)
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review [PDF]
Frontiers in Immunology, 2021 Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator
Fei Qi, Fang Liu, Ling Gao
openaire +3 more sources
Acta Dermato-Venereologica, 2023 The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh +4 more
doaj +1 more source
Tofacitinib successful treatment of idiopathic twenty-nail dystrophy: a case report
Journal of Dermatological TreatmentPurpose Twenty-nail dystrophy (TND) is a chronic nail disorder affecting all or some nails and posing a significant therapeutic challenge for dermatologists.
Wenjun Zhao, Shijun Shan, Dongmei Liu
doaj +1 more source
Janus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literature [PDF]
, 2019 Cytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors promises the start of a revolution in the treatment of several chronic diseases.
Morrissey, Hana +4 more
core +1 more source
Advances in the Inhibitors of Janus Kinase [PDF]
Medicinal Chemistry, 2014 The janus kinases (JAKs) comprise an important class of non-receptor protein tyrosine kinases. Cytokine and receptor binding can cause the activation of JAKs, and then activate the "signal transcripts and transcriptional activator”, making JAK enter the nucleus to induce target gene expression.
openaire +1 more source
Janus kinase inhibitors for the treatment of psoriatic arthritis
Indian Journal of Dermatology, Venereology and Leprology, 2023 Psoriatic arthritis (PsA), a systemic disease, has multi-domain musculoskeletal pathologies along with dermatological manifestations. The current recommendations and the standard of care for the treatment of PsA is to address the domain-based pathologies and the disease severity of the six clinical domains unique to PsA, namely, arthritis of the ...
Sanchita, Raychaudhuri +3 more
openaire +2 more sources
A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis [PDF]
Journal of Scleroderma and Related DisordersSeher Sener +2 more
exaly +2 more sources
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
, 2017 Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract.
de Jonge, Wouter +3 more
core +1 more source
Kinase inhibitors: a new class of antirheumatic drugs [PDF]
, 2012 Vasileios C KyttarisDivision of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use
Kyttaris VC, Kyttaris, Vasileios
core +1 more source
Journal of Family Medicine and Primary CareGuidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear.
Abigail Beard, Shannon C. Trotter
doaj +1 more source